Rivaroxaban shows promise in ACS secondary prevention in ATLAS
This article was originally published in Scrip
Executive Summary
Johnson & Johnson Pharmaceutical Research and Developmentand Bayerare to start a 16,000-patient Phase III study next month of their novel Factor Xa inhibitor rivaroxaban (Xarelto) in the potentially lucrative chronic use indication of ACS prevention based on encouraging Phase II data presented this week at the American Heart Association (AHA) meeting in New Orleans.